09:09 AM EDT, 07/05/2024 (MT Newswires) -- AstraZeneca ( AZN ) said on Friday that the European Union has approved its therapy, Tagrisso, in addition to pemetrexed and platinum-based chemotherapy, as the first-line treatment for certain adult patients with a type of non-small cell lung cancer.

The European Commission's approval follows the Committee for Medicinal Products for Human Use's positive opinion and is based on results from the Phase III study.

The company said Tagrisso is also under review with global regulatory authorities for patients with unresectable, Stage III EGFRm non-small cell lung cancer.

Price: 77.58, Change: +0.78, Percent Change: +1.02